Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

08:18
09/13/17
09/13
08:18
09/13/17
08:18

Intercept should be bought on weakness, says BMO Capital

BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.

TODAY'S FREE FLY STORIES

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Breaking Syndicate news story on Nutanix »

Nutanix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UAA

Under Armour; also tag UA

$13.63

-1.49 (-9.85%)

15:55
01/16/18
01/16
15:55
01/16/18
15:55
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
01/16/18
01/16
15:55
01/16/18
15:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LVS

Las Vegas Sands

$72.58

1.56 (2.20%)

15:52
01/16/18
01/16
15:52
01/16/18
15:52
Periodicals
Breaking Periodicals news story on Las Vegas Sands »

Las Vegas Sands added as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$32.35

1 (3.19%)

15:48
01/16/18
01/16
15:48
01/16/18
15:48
Hot Stocks
HomeStreet raises company-wide minimum wage to $15 per hour »

HomeStreet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HUM

Humana

$270.41

2.39 (0.89%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Options
Humana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

USB

U.S. Bancorp

$57.46

0.48 (0.84%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Hot Stocks
U.S. Bancorp names CEO Andy Cecere chairman of the board »

U.S. Bancorp, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LADR

Ladder Capital

$14.53

0.94 (6.92%)

15:39
01/16/18
01/16
15:39
01/16/18
15:39
Upgrade
Ladder Capital rating change  »

Ladder Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

ONCE

Spark Therapeutics

$52.66

-1.41 (-2.61%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Hot Stocks
Spark Therapeutics treatment of hemophilia A granted FDA orphan status »

Spark Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PX

Praxair

$161.26

-2.89 (-1.76%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Options
$6M option print in Praxair as shares deflate »

$6M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CGI

Celadon Group

$6.20

-0.4 (-6.06%)

15:26
01/16/18
01/16
15:26
01/16/18
15:26
Periodicals
Celadon Group mentioned cautiously again by Prescience Point 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGSE

RGS Energy

15:24
01/16/18
01/16
15:24
01/16/18
15:24
Hot Stocks
Iroquois Capital reports 6.3% stake in Real Goods Solar »

This activist stake held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$36.09

1.06 (3.03%)

15:20
01/16/18
01/16
15:20
01/16/18
15:20
Options
Notable spread in MGM as shares rally »

Notable spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
01/16/18
01/16
15:17
01/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/16/18
01/16
15:16
01/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

15:15
01/16/18
01/16
15:15
01/16/18
15:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

OLED

Universal Display

$196.60

-1.2 (-0.61%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Options
Universal Display call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FRME

First Merchants

$44.20

0.31 (0.71%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Hot Stocks
First Merchants announces company-wide raise, bonuses »

First Merchants announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CEO

CNOOC

$159.15

-2.1 (-1.30%)

15:04
01/16/18
01/16
15:04
01/16/18
15:04
Downgrade
CNOOC rating change  »

CNOOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$22.95

-0.8911 (-3.74%)

15:02
01/16/18
01/16
15:02
01/16/18
15:02
Recommendations
Valeant analyst commentary  »

Valeant settlement put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

UL

Unilever; also tag UN

$54.99

0.47 (0.86%)

, UN

Unilever; also tag UL

$56.07

0.575 (1.04%)

15:00
01/16/18
01/16
15:00
01/16/18
15:00
Conference/Events
Bernstein European HPC analyst holds an analyst/industry conference call »

European Food &…

UL

Unilever; also tag UN

$54.99

0.47 (0.86%)

UN

Unilever; also tag UL

$56.07

0.575 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

BTC

Bitcoin

, BITCOIN

Bitcoin

14:59
01/16/18
01/16
14:59
01/16/18
14:59
Hot Stocks
Crypto-currencies crash bringing related companies down with them »

Shares of…

BTC

Bitcoin

BITCOIN

Bitcoin

OSTK

Overstock.com

$78.95

-1.65 (-2.05%)

AMD

AMD

$12.02

-0.12 (-0.99%)

NVDA

Nvidia

$222.98

-1.1 (-0.49%)

SQ

Square

$38.71

-2.545 (-6.17%)

MARA

Marathon Patent Group

$4.17

0.33 (8.59%)

GBTC

Bitcoin Investment Trust

$1,970.00

261.995 (15.34%)

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

KODK

Kodak

$8.38

-0.8249 (-8.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

  • 30

    Jan

XLRE

Real Estate SPDR

$31.50

0.305 (0.98%)

, XLU

Utilities SPDR

$50.12

-0.14 (-0.28%)

14:58
01/16/18
01/16
14:58
01/16/18
14:58
Technical Analysis
Technical Take: S&P 500 breaks support, sector breadth negative »

The downward move in the…

XLRE

Real Estate SPDR

$31.50

0.305 (0.98%)

XLU

Utilities SPDR

$50.12

-0.14 (-0.28%)

XLP

Consumer Staples Sector SPDR

$56.86

0.205 (0.36%)

XLK

Technology Select Sector SPDR

$66.51

-0.3 (-0.45%)

XLF

Financial Select Sector

$29.06

-0.17 (-0.58%)

XLY

Consumer Discretionary Sector SPDR

$104.21

-0.82 (-0.78%)

XLB

S&P Select Materials SPDR

$62.43

-0.965 (-1.52%)

XLE

Energy Select Sector SPDR

$76.46

-0.9599 (-1.24%)

SPY

SPDR S&P 500 ETF Trust

$276.69

-1.23 (-0.44%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$75.51

0.89 (1.19%)

14:55
01/16/18
01/16
14:55
01/16/18
14:55
Options
Colgate Palmolive put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

14:55
01/16/18
01/16
14:55
01/16/18
14:55
Conference/Events
Stephens real estate services analyst holds an analyst/industry conference call »

Analysts, along with Jeff…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.